
Deferasirox tablets
Form: Tablet
Strength: 125 mg, 250 mg, and 500 mg
Reference Brands: Exjade(Dispersible tablets);Jadenu (Film-coated Tablet)s
Category: Blood Disorder
Deferasirox tablets, marketed as Exjade and Jadenu, are approved in the US by the FDA and in the EU via EMA for treating chronic iron overload in transfusion-dependent patients. Regulatory approval requires a comprehensive dossier including clinical data, manufacturing quality, safety, efficacy, and pharmacovigilance plans. In the US, FDA review involves detailed assessment, while EMA approval follows strict regional guidelines, ensuring consistent quality standards. For expert guidance on dossier preparation, regulatory pathways, and successful market access, visit PharmaTradz. Compliance with regional regulations is essential for the safe, effective, and timely approval of deferasirox tablets worldwide, supporting optimal patient management.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Anti-Inhibitor Coagulant Complex (AICC) Lyophilized Powder
Strength: 500 units, 1000 units, and 2500 units
Form: Lyophilized Powder (Reconstituted for IV infusion)
Reference Brands: FEIBA(US)
View Details Get EnquiryProthrombin Complex Concentrate (PCC) injection
Strength: 250 IU to 300 IU
Form: Injection
Reference Brands: Kcentra (4-factor PCC), Bebulin VH (3-factor PCC)(US)
View Details Get EnquiryMesna Injection
Strength: 100 mg/mL
Form: Injection
Reference Brands: Mesnex(US)
View Details Get EnquiryLeucovorin tablets/Capsule
Strength: 15 mg, 50 mg
Form: Tablet/Capsules
Reference Brands: Folvite(US & EU)
View Details Get Enquiry